Overview

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Phase II trial of nivolumab in 120 treatment naïve patients with ccRCC.
Phase:
Phase 2
Details
Lead Sponsor:
Michael B. Atkins, MD
Collaborators:
Bristol-Myers Squibb
Hoosier Cancer Research Network
Treatments:
Antibodies, Monoclonal
Ipilimumab
Nivolumab